ReviewHuman vaccines & immunotherapeutics2014
The future for vaccine development against Entamoeba histolytica.
Review in Human vaccines & immunotherapeutics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 74 citations in OpenAlex.
- Fulminant Amebic Colitis after Corticosteroid Therapy: A Systematic Review.PLoS neglected tropical diseases · 2016Pooled it
- Amebiasis as a neglected tropical disease: Current knowledge gaps and future directions.PLoS neglected tropical diseases · 2026Review
- Structural insights into interdomain interactions inJournal of structural biology: X · 2026Article
- Immunogenicity and safety of anHuman vaccines & immunotherapeutics · 2024Article
- Molecular characterisation of Entamoeba histolytica UDP-glucose 4-epimerase, an enzyme able to provide building blocks for cyst wall formation.PLoS neglected tropical diseases · 2023Article
- Review
- Pleiotropic Roles of Cholesteryl Sulfate duringmSphere · 2022Article
- Are Metabolites From the Gut Microbiota Capable of Regulating Epigenetic Mechanisms in the Human ParasiteFrontiers in cell and developmental biology · 2022Review
- Stage-SpecificmSphere · 2021Article
- Entamoeba histolytica: Five facts about modeling a complex human disease in rodents.PLoS pathogens · 2020Article
- The dynamics of ultrastructural changes duringParasitology · 2020Article
- Antigenic membrane proteins of virulent variant ofPathogens and global health · 2020Article
- Ongoing transmission of Entamoeba histolytica among newly diagnosed people living with HIV in Taiwan, 2009-2018.PLoS neglected tropical diseases · 2020Article
- Anti-amebic effects of Chinese rhubarb (Heliyon · 2020Article
- Review
- Significance of amebiasis: 10 reasons why neglecting amebiasis might come back to bite us in the gut.PLoS neglected tropical diseases · 2019Article
- Unique Features ofInternational journal of molecular sciences · 2019Review
- Characterization of Entamoeba histolytica adenosine 5'-phosphosulfate (APS) kinase; validation as a target and provision of leads for the development of new drugs against amoebiasis.PLoS neglected tropical diseases · 2019Article
- Comparative Pathobiology of the Intestinal Protozoan ParasitesPathogens (Basel, Switzerland) · 2019Review
- Host-antibody inductivity of virulent Entamoeba histolytica and non-virulent Entamoeba moshkovskii in a mouse model.Parasites & vectors · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 3 countries.
Funding
Abstract
Entamoeba histolytica is the causative agent of amebiasis, one of the top three parasitic causes of mortality worldwide. In the majority of infected individuals, E. histolytica asymptomatically colonizes the large intestine, while in others, the parasite breaches the mucosal epithelial barrier to cause amebic colitis and can disseminate to soft organs to cause abscesses. Vaccinations using native and recombinant forms of the parasite Gal-lectin have been successful in protecting animals against intestinal amebiasis and amebic liver abscess. Protection against amebic liver abscesses has also been reported by targeting other E. histolytica components including the serine-rich protein and the 29-kDa-reductase antigen. To date, vaccines against the Gal-lectin hold the most promise but clinical trials will be required to validate its efficacy in humans. Here, we review the current strategies and future perspectives involved in the development of a vaccine against E. histolytica.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.